Ion mobility is a powerful extension to mass spectrometry that delivers information about the three dimensional structure ... characterization. timsTOF was engineered by Bruker experts as an ...

Similar improvements are observed in immunopeptidomics. Bruker expects to launch the new AIP on the timsTOF Ultra 2 system at ASMS 2025 with timsTOF Ultra 2 field upgradability. B. DeutEx ...

Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 ...

Bruker announced significant advances in 4D-Proteomics performance, software and applications for deeper biological insights. These include the novel Athena Ion Processor (AIP) on the timsTOF ...

Good day, and welcome to the Bruker Corporation Fourth Quarter 2024 ... we could certainly do that. Yes. So timsTOF is doing better again. Obviously, we had some competitive dynamics there when ...

2025 Non-GAAP EPS Guidance: $2.67 to $2.72, representing 11% to 13% growth. Bruker Corp (NASDAQ:BRKR) reported a strong Q4 2024 with a 14.6% year-over-year increase in revenues, reaching $979.6 ...

Bruker (BRKR) reported $979.6 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 14.6%. EPS of $0.76 for the same period compares to $0.70 a year ago.

In this article, we are going to take a look at where Bruker Corporation (NASDAQ:BRKR) stands against the other medical technology stocks. The MedTech sector is crucial in healthcare, which ...

In its fourth quarter 2024 investor letter, The London Company SMID Cap Strategy emphasized stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on developing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...